Luis Lizardi

Molecular Oncology Account Executive

[Caris Life Sciences @carisls]

Not all liquid biopsy results are created equal, especially when clonal hematopoiesis (CH) can complicate interpretation and lead to off-target cancer therapy.

Caris Assure® addresses this challenge by directly sequencing plasma and matched white blood cells, helping clinicians focus on tumor-derived alterations with greater confidence.

When tissue is limited or unavailable, this approach supports more informed treatment decisions.

Learn more: https://t.co/Vzvs9E9xUx

[Caris Life Sciences @carisls]

Fragmented genetic testing can limit insight into myeloid malignancies. Caris ChromoSeq consolidates multiple methods into one Whole Genome Sequencing (WGS) assay, delivering a comprehensive view to support diagnosis and risk stratification. Learn more: https://t.co/zwnhSl7WVp

[Caris Life Sciences @carisls]

A clearer view of cancer recurrence risk right from the start. Caris MI Clarity™ supports informed decision-making in early-stage breast cancer. Learn more: https://t.co/PwaaimAIBB

[Caris Life Sciences @carisls]

The future of cancer detection looks deeper.

Caris Detect™ was designed to be the most advanced MCED test ever created—analyzing all DNA and RNA to identify cancer-associated molecular signals that other approaches may miss.

Learn more and order through Everlywell at https://t.co/tTtKtnq53f

[Caris Life Sciences @carisls]

Conventional testing for myeloid malignancies often requires multiple genetic tests and reports.

In this webinar, Mark Evans, MD, and Lukasz Gondek, MD, PhD, will discuss how Caris ChromoSeq™ uses high-coverage Whole Genome Sequencing (WGS) to support diagnosis, risk stratification and treatment selection through one integrated report.
Resister now:

Resister now: https://t.co/6zk0Yz3CbL

[Caris Life Sciences @carisls]

MI Cancer Seek® provides profiling of solid tumors using both Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) technologies. FDA-approved for both adult and pediatric patients (ages 1+). Learn more & view important product info: https://t.co/NA6gt04Qb3

[Caris Life Sciences @carisls]

When treatment decisions can depend on a single molecular finding, confidence and accuracy matter. The goal is not simply to detect more signals — it's to deliver clinically actionable findings that can help physicians guide treatment decisions with confidence.

Learn more about Caris Assure®: https://t.co/S2bz7BKasK

[Caris Life Sciences @carisls]

MI Cancer Seek® combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) into a single assay with FDA-approved CDx indications for solid tumors. This integrated approach enables deeper molecular understanding to help inform treatment decisions for both adult and pediatric patients (ages 1+).

Discover more and view important product information: https://t.co/eF0nqXHBAj

[Caris Life Sciences @carisls]

Knowing more about your risk of breast cancer returning may help you feel more prepared for what’s ahead. Ask your doctor if Caris MI Clarity™ may be right for you and how its insights could help guide conversations about your ongoing care. https://t.co/qMpHlUHj41

[Caris Life Sciences @carisls]

Today, Caris President David Spetzler discussed how Caris is using Amazon Omics Sequence Stores and Variant Stores to store a comprehensive set of real-world #oncology data during #BioIT23.

#artificialintelligence
#precisiononcology

[Caris Life Sciences @carisls]

The Caris Molecular Tumor Board provides #oncologists with the opportunity to interact with leading #cancerexperts from across the country to obtain interpretations of molecular findings and therapeutic guidance for individual patients.
Learn more: https://t.co/dOrEiKhuFL

[Luis Lizardi @lizardiluis13]

Love what we do with Signatera. Love working at Natera where we are making a difference in cancer patient's lives.

https://t.co/E7EI64Knx2

[Luis Lizardi @lizardiluis13]

Exciting news! Continuing to lead the way to advance patient care.

[Natera Oncology @NateraOncology]

We are pleased to share that Medicare has extended coverage of #Natera’s Signatera MRD test to #BreastCancer. Coverage applies across all subtypes of the disease, including hormone receptor (HR)-positive, HER2-positive, and triple negative breast cancers. https://t.co/YJvdqT87VB

[Luis Lizardi @lizardiluis13]

@Hamez76 @CoachAcostaJ @MiamiDolphins I’m excited lol

[Luis Lizardi @lizardiluis13]

@MWollenweber @AGJeffLandry Confusion? The only people confused are the adults. There was never any confusion in the past. My child, my responsibility. End of story.

[Luis Lizardi @lizardiluis13]

@Hamez76 @CoachAcostaJ Man what a game!!!

[Natera Oncology @NateraOncology]

Natera’s #Signatera #MRD test has officially met coverage requirements for patients with muscle invasive #BladderCancer (#MIBC).

Learn more about CMS Molecular Diagnostics Services Program’s decision, and what it means for people with bladder cancer. https://t.co/Yg26dG1GkW

[Natera Oncology @NateraOncology]

Discover how #Signatera, a personalized blood test designed to track mutations specific to each person's tumor, can be used to help better assess an individual's response to #immunotherapy and identify cancer progression. https://t.co/RdwzMHEBlw
#StrongBetweenScans #CIM22

[Luis Lizardi @lizardiluis13]

https://t.co/RDjfTmsgjy